AnGes To Withdraw, Refile HGF Gene Therapy In Japan

 
• By Lisa Takagi

If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.

AnGes will once pull out Collategen from the Japanese market, and then refile for approval.
AnGes will pull Collategene from Japanese market then refile for approval • Source: Shutterstock

More from Japan

More from Focus On Asia